Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $231

Benzinga Newsdesk www.benzinga.com Positive 79.3%

Neg 0% Neu 0% Pos 79.3%

Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $210 to $231.